Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

Despite the therapeutic efficacy of ibrutinib in chronic lymphocytic leukemia (CLL), complete responses are infrequent, and acquired resistance to Bruton agammaglobulinemia tyrosine kinase (BTK) inhibition is being observed in an increasing number of patients. Combination regimens that increase freq...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Hing, Zachary A., Mantel, Rose, Beckwith, Kyle A., Guinn, Daphne, Williams, Erich, Smith, Lisa L., Williams, Katie, Johnson, Amy J., Lehman, Amy M., Byrd, John C., Woyach, Jennifer A., Lapalombella, Rosa
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2015
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4432007/
https://ncbi.nlm.nih.gov/pubmed/25838351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-621391
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker